Skip to main content
    R

    Redhill Biopharma Ltd (RDHL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.50
    +0.01 (+2.65%)

    Market Cap: $4.58M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    41%(11/27)
    Avg Surprise
    -119.85%
    PeriodReportedEst.SurpriseB/MYoY
    Dec 25
    Reported Mar 30
    		$0.00$0.00N/ABeat+100.0%
    Sep 25
    Reported Dec 2
    		$0.00$0.00N/ABeat-
    Jun 25
    Reported Sep 5
    		$-2.29$0.00N/AMiss+98.9%
    Mar 25
    Reported Apr 10
    		$-4.02$0.00N/AMiss-1910.0%
    Dec 24
    Reported Mar 31
    		$-4.02$0.00N/AMiss-1910.0%
    Sep 24
    Reported Oct 3
    		$0.00$0.00N/ABeat-
    Jun 24
    Reported Aug 29
    		$-200.00$-30.00-566.67%Miss-78500.6%
    Mar 24
    Reported Apr 8
    		$-0.20$-0.03-566.67%Miss+87.5%
    Dec 23
    Reported Feb 12
    		$-0.20$-0.03-566.67%Miss+0.0%
    Sep 23
    Reported Dec 29
    		$0.00$0.00N/ABeat+100.0%
    Jun 23
    Reported Aug 17
    		$0.26$0.00N/ABeat+227.6%
    Mar 23
    Reported Jun 12
    		$-1.60$0.00N/ABeat+94.7%
    Dec 22
    Reported Mar 27
    		$-0.20$0.00N/AMiss+100.0%
    Sep 22
    Reported Nov 7
    		$-60.00$-10.00-500.00%Miss-20.0%
    Jun 22
    Reported Sep 23
    		$-0.20$-0.03-566.67%Miss+100.0%
    Mar 22
    Reported Jun 23
    		$-30.00$-30.00+0.00%Beat+94.0%
    Dec 21
    Reported Mar 17
    		$-500.00$-430.00-16.28%Miss-71328.6%
    Sep 21
    Reported Nov 30
    		$-50.00N/A+82.27%Beat+90.0%
    Jun 21
    Reported Aug 26
    		$-600.00$-248.00-141.94%Miss-1400.0%
    Mar 21
    Reported May 27
    		$-500.00$-278.00-79.86%Miss+0.0%
    Dec 20
    Reported Mar 18
    		$-0.70$-0.24-191.67%Miss+99.8%
    Sep 20
    Reported Nov 12
    		$-499.82$-185.00-170.17%Miss-66.6%
    Jun 20
    Reported Aug 13
    		$-40.00N/A+55.56%Beat+90.0%
    Mar 20
    Reported May 27
    		$-500.00$-600.00+16.67%Beat-66.7%
    Dec 19
    Reported Mar 4
    		$-300.00$-237.50-26.32%Miss-99900.0%
    Sep 19
    Reported Nov 19
    		$-300.00$-292.50-2.56%Miss+25.0%
    Jun 19
    Reported Jul 23
    		$-400.00$-346.67-15.38%Miss-79900.0%
    Mar 19
    Reported May 7
    		$-300.00$-346.67+13.46%Beat+40.0%
    Dec 18
    Reported Feb 26
    		$-0.30$-0.38+21.05%Beat+40.0%
    Sep 18
    Reported Nov 13
    		$-400.00$-413.33+3.23%Beat+55.6%
    Jun 18
    Reported Aug 30
    		$-0.50$-0.44-13.64%Miss+99.9%
    Mar 18
    Reported May 8
    		$-500.00$-463.33-7.91%Miss-99900.0%
    Dec 17
    Reported Feb 22
    		$-0.50$-0.60+16.67%Beat+99.9%
    Sep 17
    Reported Nov 13
    		$-900.00$-636.67-41.36%Miss-
    Jun 17
    Reported Jul 25
    		$-600.00$-620.00+3.23%Beat-
    Mar 17
    Reported May 3
    		$-0.50$-0.57+12.28%Beat-
    Dec 16
    Reported Feb 23
    		$-600.00$-693.33+13.46%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1709.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage66.17x
    Current Ratio0.34xQuick Ratio0.34x
    Trading Statistics
    Beta4.90Avg Volume855.16K
    52-Week High$2.1452-Week Low$0.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.51
    SMA 20$0.51
    SMA 50$0.59
    SMA 200$0.85
    EMA 10$0.51
    EMA 20$0.53
    EMA 50$0.59
    EMA 200$0.87

    MACD

    Line: -0.03Signal: -0.03Hist: 0.01

    ADX

    ADX: 25.0+DI: 31.9-DI: 17.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down80.0
    PSAR$0.46

    Bollinger Bands

    Upper Band$0.58
    Lower Band$0.45
    %B Position2446%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    43.1

    Momentum Oscillators

    Stoch %K25.4
    Stoch %D30.7
    Williams %R-75.0
    ROC (10d)4.0%
    Momentum0.02
    CCI (20d)-48.1
    MFI (14d)92.1

    Volatility Measures

    ATR (14d)$0.06(11.3%)
    StdDev (20d)0.03
    Hist Vol95.2%(High)

    Volume Flow

    VWAP$0.50
    OBV251.8M
    AD Line-142.4M
    CMF (20d)0.059

    Volume Metrics

    Avg Vol (20d)918.0K
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.57

    Pivot Points

    R3$0.53
    R2$0.52
    R1$0.50
    Pivot Point$0.49
    S1$0.47
    S2$0.46
    S3$0.44

    Advanced Oscillators

    TSI-15.29
    Ultimate Osc43.5
    KST-170.03

    Financial Data

    QuarterJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total Revenue$2.04M$2.04M$2.74M$2.74M$1.29M$1.29M$567,500$567,500$1.80M$12.80M$12.80M$17.55M
    Cost of Revenue$803,500$803,500$894,000$894,000$702,000$702,000$520,499$520,499$806,000$8.60M$8.60M$9.45M
    Gross Profit$1.24M$1.24M$1.84M$1.84M$584,000$584,000$47,000$47,000$990,000$4.20M$4.20M$8.10M
    Operating Expenses$3.42M$3.42M$4.92M$4.92M$4.81M$4.81M$6.07M$6.07M$5.40M$14.15M$14.15M$15.21M
    R&D$482,000$482,000$464,500$464,500$329,500$329,500$598,500$598,500$1.25M$1.13M$1.13M$1.61M
    SG&A$1.93M$1.93M$3.28M$2.05M$2.73M$2.73M$6.00M$3.44M$3.54M$32.88M$32.88M$6.50M
    Operating Income$-2,189,000$-2,189,000$-3,082,500$-3,082,500$-4,224,000$-4,224,000$-6,020,000$-6,020,000$-4,408,000$-9,948,000$-9,948,000$-7,108,000
    Interest Income$0$0$913,000$0$0$0$1.04M$0$7.09M$21.58M$4.72M$3.19M
    Interest Expense$512,000$512,000$0$0$874,000$874,000$0$7.52M$1.93M$1.43M$1.43M$31.78M
    Income Before Tax$-2,066,500$-2,066,500$-2,590,000$-2,590,000$-1,544,000$-1,544,000$-13,543,000$-13,543,000$761,000$-3,729,000$-3,729,000$-35,701,000
    Income Tax Expense$0$0$0$0$0$0$0$0$421,000$-6,219,000$-6,219,000$28.59M
    Net Income$-2,066,500$-2,066,500$-2,590,000$-2,590,000$-1,544,000$-1,544,000$-13,543,000$-13,543,000$761,000$-3,729,000$2.49M$-35,701,000
    EBITDA$-2,105,000$-2,105,000$-1,878,500$-1,802,500$-4,014,999$-4,014,999$-5,841,500$-5,817,500$2.69M$-294,000$-294,000$-1,826,000
    EBIT$-2,189,000$-2,189,000$-1,903,000$-1,903,000$-4,223,999$-4,223,999$-6,020,000$-6,020,000$61.59M$-2,302,000$-9,948,000$-3,918,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RDHL

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Each depositary share represents 10,000 ordinary shares at RedHill Biopharma (RDHL).

    RedHill Biopharma has increased the maximum aggregate offering amount of its American Depositary Shares (ADSs) under an at-the-market offering agreement with H.C. Wainwright & Co....

    Stock Titan•10/13/26•Neutral

    Nasdaq gives RedHill Biopharma (NASDAQ: RDHL) more time to clear its $1 bid-price hurdle

    RedHill Biopharma Ltd. (NASDAQ: RDHL) has been granted an additional 180 calendar days by Nasdaq, until April 5, 2027...

    Stock Titan•10/7/26•Neutral

    Form 4 RedHill Biopharma Ltd. For: 6 October By Investing.com

    This article announces the filing of Form 4 by RedHill Biopharma Ltd. on October 6th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade...

    Investing.com UK•10/6/26•Neutral

    RedHill Biopharma Ltd. (RDHL) Stock Price, News, Quote & History

    This article provides an overview of RedHill Biopharma Ltd. (RDHL), a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. It includes current stock performance, key financial metrics...

    Yahoo! Finance Canada•10/2/26•Neutral

    One dose showed over 70% success preventing repeat infections from C. diff bacteria. RedHill acquired its rights.

    RedHill Biopharma reported operational highlights and first-half 2026 financial results, including a net loss of $6.102 million. The company acquired global commercialization rights for Rebyota and U.S. rights...

    Stock Titan•9/30/26•Bullish

    RDHL Valuation and Fair Value

    Forward P/E
    1428.6x
    PEG
    0.0x
    P/B
    1.0x
    See GNG's fair value

    RDHL Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -1709.0%

    RDHL Competitors

    CompanyTicker
    XTL Biopharmaceuticals Ltd ADRXTLB
    bioAffinity Technologies, Inc.BIAF
    Intelligent Bio Solutions Inc.INBS
    Vivos Therapeutics IncVVOS
    Gelteq Limited Ordinary SharesGELS
    Enlivex Therapeutics LtdENLV
    Xenetic Biosciences IncXBIO
    NuCana PLCNCNA

    Sector: Healthcare

    RDHL Bull Case vs Bear Case

    Bull case

    • RDHL grew quarterly revenue 58.6% year over year.

    Bear case

    • RDHL beat EPS estimates in 0.0% of its last 8 reported quarters.

    RDHL Earnings: Beat Rate and Next Report

    Beat rate
    0 of 8 quarters (0.0%)
    Average surprise
    -566.7%

    Frequently Asked Questions About RDHL

    Does RDHL pay dividends?

    Redhill Biopharma Ltd (RDHL) does not currently pay a regular dividend.

    What is RDHL's market cap?

    Redhill Biopharma Ltd (RDHL) has a market capitalization of $4.58M with a current stock price of $0.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In